Penn Medicine Provider
Medical Oncology
Charu Aggarwal, MD, MPH
5.0
(114)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West

About me

  • Physician Leader, Airways Malignancies Research
  • Director, Precision Oncology Innovation, Penn Center for Cancer Care Innovation
  • Section Chief, Head & Neck and Thoracic Cancers, Hematology-Oncology
  • Leslye M. Heisler Professor for Lung Cancer Excellence

Dr. Aggarwal specializes in the management of patients with lung cancer. Her clinical research focus is on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principal investigator for multiple clinical trials focusing on the development of targeted immunotherapy approaches.

Education and training

  • Medical School: Lady Hardinge Medical College
  • Residency: University at Buffalo, Jacobs School of Medicine and Biomedical Sciences
  • Fellowship: Fox Chase Cancer Center

What my patients think about me

Average Rating
5.0

114 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
great team!!
March 2025
5.0
5.0
went into detail explanation on my ct scan
February 2025
5.0
5.0
she is super knowledgeable and a very caring woman. she was genuine and truly cares about my health
February 2025
5.0
5.0
super caring

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Aggarwal is a Penn Medicine physician.

Qualifications and experience

My research

Teja Voruganti, Rosalyn Marar, Benjamin Bleiberg, Edoardo Garbo, Biagio Ricciuti, Kaushal Parikh, Charu Aggarwal Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions , American Society of Clinical Oncology Educational Book, 45(3): 2025


Adam Barsouk, Omar Elghawy, Alex Watts, Lauren Reed-Guy, William Tompkins, Krishna Chandrasekhara, Connor B Grady, Wade Iams, Fangdi Sun, Geoffrey Liu, Devalben Patel, Jorge J Nieva, Kristen A Marrone, Vamsidhar Velcheti, Stephen V Liu, Tejas Patil, Jared Weiss, William Schwartzman, Liza C Villaruz, Amanda Hermann, Dara L Aisner, Wei-Ting Hwang, D Ross Camidge, Lova Sun, Aditi Puri Singh, Roger B Cohen, Charu Aggarwal, Corey J Langer, Melina E Marmarelis Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis , Lung Cancer, 203: 2025


Sun L, Marmarelis ME, Aggarwal C. Management of Patients With EGFR Exon 20-Mutant Advanced Non-Small Cell Lung Cancer , Journal of Clinical Oncology: 2025


Melina E Marmarelis, Adrienne M Gilligan, Tomoko Sugihara, Shen Zheng, Tyler Marquart, Sam Whipple, Naleen Raj Bhandari, Charu Aggarwal HSR25-167: Real-World Study Demonstrates Lack of Biomarker-driven Care in First-Line Treatment for Advanced/Metastatic Non-Small Cell Lung Cancer That Received Next-Generation Sequencing Testing , Journal of the National Comprehensive Cancer Network, 23(3.5): 2025


Stalker M, Marmarelis M, Langer C, Cohen RB, Singh A, Aggarwal C, Sun L. Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC , Clin Lung Cancer, 26(2): 2025,124-130


Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C. Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy , Clin Lung Cancer, 26(2): 2025,158-163


Reuss JE, Zaemes J, Gandhi N, Walker P, Patel SP, Xiu J, Aggarwal C, Vanderwalde A, Ramalingam SS, Halmos B, Liu SV. Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking , Lung Cancer, 200: 2025


Stabellini N, Makram OM, Kunhiraman HH, Daoud H, Shanahan J, Montero AJ, Blumenthal RS, Aggarwal C, Swami U, Virani SS, Noronha V, Agarwal N, Dent S, Guha A. A novel machine learning-based cancer-specific cardiovascular disease risk score among patients with breast, colorectal, or lung cancer , JNCI Cancer Spectr, 9: 2025,pkaf016


Horgan D, Tanner M, Aggarwal C, Thomas D, Grover S, Basel-Salmon L, Dienstmann R, Tan TJY, Park WY, Abu Rasheed HM, Siu LL, Ma B, Ortiz-López R, Van den Bulcke M, Taucher SC, Ferris A, Starling N, Malapelle U, Longshore J, Saldaña HAB, Subbiah V. Precision Oncology: A Global Perspective on Implementation and Policy Development , JCO Glob Oncol, 11: 2025


Grady CB, Hwang WT, Reuss JE, Iams W, Cass A, Liu G, Patel D, Liu SV, Montenegro GLB, Patil T, Nieva JJ, Herrmann A, Marrone KA, Lam VK, Schwartzman W, Dowell J, Villaruz LC, Miller KL, Weiss J, Sun F, Velcheti V, Camidge DR, Aggarwal C, Sun L, Marmarelis ME. Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer , Pharmacoepidemiol Drug Saf: 2024